A pipeline-first board: instead of guessing which diseases to watch, we watch what actually changed — a candidate moving stage, earning an FDA designation, being approved, or being withdrawn — and show it dated, sourced, and in plain language. Withdrawals count as movement too. A board that only reported advances would mislead the people it serves.
About the data in this mock: every candidate below uses an obviously-sample name (for example, SAMPLE-101) paired with a real disease name, and every card is labelled SAMPLE. The dates and sources are illustrative placeholders. Nothing here describes a real drug, trial, or announcement.
The movers nearest to approval — in Phase 3, in FDA review, or recently approved — ranked by pipeline position only. Position is not a promise: candidates fail in Phase 3 and even in review, closer does not mean more likely to help you, and an approval is not a cure. This list follows the same filters and search as the board below.
Every card carries the same information and the same weight — including the withdrawal. Read “What this means” on each card: it states plainly what the movement does not mean, as well as what it does.
No sample movers match those filters.
Try a different disease name, movement type, or stage.
A treatment candidate travels a long road before anyone can be prescribed it. Most candidates never finish the journey — they fail, often in the later, larger stages. Each step below is written the way we describe it on the cards.
Tested in a lab — in cells or in animals — not in people. A result here is a lab result, nothing more. It is not a treatment and may never become one.
A small group of people, mainly to check safety and find a workable dose. This stage does not prove the candidate works.
A larger group. Researchers look for early signs it helps, and keep watching side effects. Many candidates stop here.
A large study, usually comparing the candidate against standard care or a placebo. This is the main evidence regulators weigh — and candidates still fail here.
The regulator examines all the data and can approve it, refuse it, or ask for more evidence. Review commonly takes many months. Being “in review” is not approval.
It can be prescribed for the use that was studied. It is still monitored for side effects. Approved does not mean cured, and does not mean it helps everyone with the condition.
Two labels to know: an FDA designation (Breakthrough Therapy or Fast Track) is a process benefit — more guidance and potentially faster review. It changes how the FDA works with the sponsor; it does not change what the evidence shows, and it is not an approval. A withdrawal means development stopped or a product was pulled — disappointing news we show at full size, because hiding it would make every other card on this board less trustworthy.
The long-term idea: pick a disease and get an alert whenever something for it moves on this board — a personal “waiting list” for the pipeline.
Alerts are not open yet, on purpose. They arrive only after the weekly movers feed has proved it can stay accurate, dated, sourced, and current. Sending alerts from an unproven feed would risk giving people false hope or stale news about their own health.
There is no sign-up in this mock — nothing to enter, nothing sent anywhere, no account.